Conditions: Metastatic Renal Cell Carcinoma
Keywords: Unresectable advanced or metastatic renal cell carcinoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 173
Healthy volunteers: no

Brief summary:
This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Lenvatinib intervention 2: Everolimus
Intervention descriptions: intervention 1: taken orally, once a day intervention 2: taken orally, once a day

Protocol document: